<DOC>
	<DOCNO>NCT03049657</DOCNO>
	<brief_summary>Clinical trial `` European Community mark '' medical device patient ischemic heart disease clinical indication coronary revascularization drug-eluting stent . Clinical follow-up do accord way : first month telephone face-to-face interview 6 ± 1 month Angiography follow + OCT ( optical coherence tomography ) A randomized clinical trial compare efficacy Angiolite Stent versus second-generation drug-eluting stent Xience stent . ( non-inferiority design )</brief_summary>
	<brief_title>Efficacy Angiolite Stent v Second-generation Drug-eluting Stent Xience Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patients clinical subclinical ischemic heart disease indication percutaneous revascularization . `` De Novo '' lesion ≥ 70 % Reference diameter ≥ 2 mm ≤ 4 mm Accepted participation registration signing informed consent Cardiogenic shock Pregnancy Intolerance allergy anti platelet anticoagulant therapy Elective surgical procedure schedule within 6 month inclusion study Expectancy life less 1 year . Impossibility 1 year clinical followup . Primary angioplasty patient killip class IIIIV mechanical complication . Patient preprocedure restenosis . Patients treat lesion Angiolite stent . Total occlusion Truncus disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>